Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids.

• Kanemitsu, Yoshihiro

• 松本, 久子

• Izuhara, Kenji

• Tohda, Yuji

• Kita, Hideo

• Horiguchi, Takahiko

• Kuwabara, Kazunobu

• Tomii, Keisuke

• Otsuka, Kojiro

• Fujimura, Masaki

• Ohkura, Noriyuki

• Tomita, Katsuyuki

• Yokoyama, Akihito

• Ohnishi, Hiroshi

• Nakano, Yasutaka

• Oguma, Tetsuya

• Hozawa, Soichiro

• Nagasaki, Tadao

• Ito, Isao

• Oguma, Tsuyoshi

• Inoue, Hideki

• Tajiri, Tomoko

• Iwata, Toshiyuki

• Izuhara, Yumi

• Ono, Junya

• Ohta, Shoichiro

• Tamari, Mayumi

• Hirota, Tomomitsu

• Yokoyama, Tetsuji

• Niimi, Akio

• Mishima, Michiaki

抄録

[Background]Periostin, an extracellular matrix protein, contributes to subepithelial thickening in asthmatic airways, and its serum levels reflect airway eosinophilic inflammation. However, the relationship between periostin and the development of airflow limitation, a functional consequence of airway remodeling, remains unknown. [Objective]We aimed to determine the relationship between serum periostin levels and pulmonary function decline in asthmatic patients on inhaled corticosteroid (ICS) treatment. [Methods]Two hundred twenty-four asthmatic patients (average age, 62.3 years) treated with ICS for at least 4 years were enrolled. Annual changes in FEV1, from at least 1 year after the initiation of ICS treatment to the time of enrollment or later (average, 16.2 measurements over 8 years per individual), were assessed. At enrollment, clinical indices, biomarkers that included serum periostin, and periostin gene polymorphisms were examined. Associations between clinical indices or biomarkers and a decline in FEV1 of 30 mL or greater per year were analyzed. [Results]High serum periostin levels (≥95 ng/mL) at enrollment, the highest treatment step, higher ICS daily doses, a history of admission due to asthma exacerbation, comorbid or a history of sinusitis, and ex-smoking were associated with a decline in FEV1 of 30 mL or greater per year. Multivariate analysis showed that high serum periostin, the highest treatment step, and ex-smoking were independent risk factors for the decline. Polymorphisms of periostin gene were related to higher serum periostin levels (rs3829365) and a decline in FEV1 of 30 mL or greater per year (rs9603226). [Conclusions]Serum periostin appears to be a useful biomarker for the development of airflow limitation in asthmatic patients on ICS.

収録刊行物

• The Journal of allergy and clinical immunology

  The Journal of allergy and clinical immunology 132 (2), 305-312.e3, 2013-08

  Mosby, Inc.

キーワード

• Asthma
• inhaled corticosteroids
• lung function decline
• periostin
• POSTN gene polymorphism
• sinusitis
• treatment step
• Administration, Inhalation
• Adrenal Cortex Hormones/administration & dosage
• Adrenal Cortex Hormones/therapeutic use
• Aged
• Airway Remodeling/drug effects
• Anti-Asthmatic Agents/administration & dosage
• Anti-Asthmatic Agents/therapeutic use
• Asthma/drug therapy
• Asthma/genetics
• Asthma/physiopathology
• Biological Markers/metabolism
• Cell Adhesion Molecules/blood
• Cell Adhesion Molecules/genetics
• Female
• Humans
• Lung/physiopathology
• Male
• Middle Aged
• Polymorphism, Genetic
• Respiratory Function Tests
• Up-Regulation

詳細情報

• CRID: 1050564285731376256
• NII論文ID: 120005342661
• NII書誌ID: AA00692442
• ISSN: 00916749
• HANDLE: 2433/179319
• 本文言語コード: en
• 資料種別: journal article
• データソース種別:
  • IRDB
  • CiNii Articles